Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Oxford BioDynamics ( (GB:OBD) ) has provided an announcement.
Oxford BioDynamics Plc announced its preliminary results for the year ending September 2025, highlighting significant growth in its EpiSwitch® Prostate Screening Test orders and a successful £7 million fundraising effort. The company has made strategic advancements, including a partnership with Google Cloud and ongoing discussions for third-party collaborations, positioning itself for further growth and increased shareholder value.
The most recent analyst rating on (GB:OBD) stock is a Sell with a £0.50 price target. To see the full list of analyst forecasts on Oxford BioDynamics stock, see the GB:OBD Stock Forecast page.
Spark’s Take on GB:OBD Stock
According to Spark, TipRanks’ AI Analyst, GB:OBD is a Underperform.
Oxford BioDynamics’ stock score is primarily impacted by its challenging financial performance, characterized by consistent losses and negative cash flows. Technical analysis indicates bearish momentum, and valuation metrics are unfavorable due to a negative P/E ratio. These factors collectively suggest a high-risk investment with significant financial and operational challenges.
To see Spark’s full report on GB:OBD stock, click here.
More about Oxford BioDynamics
Oxford BioDynamics Plc is a precision clinical diagnostics company that specializes in developing specific and sensitive tests based on its EpiSwitch® 3D genomics platform. The company focuses on advancing clinical diagnostics in areas such as cancer and chronic fatigue syndrome, with a market focus on both the UK and the US.
Average Trading Volume: 31,803,538
Technical Sentiment Signal: Strong Sell
Current Market Cap: £10.94M
See more data about OBD stock on TipRanks’ Stock Analysis page.